Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib for Lymphangioleiomyomatosis (LAM)
NCT03062943Phase 2Completed
- Sponsor
- MultiMedica
- Start
- Dec 2016
- Primary completion
- Dec 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nintedanib in lymphangioleiomyomatosis (LAM), sponsored by MultiMedica. Primary endpoint: Forced Expiratory Volume in 1 second rate decline at 12 months. Started Dec 2016; status: completed.
02
Drugs
nintedanib
03
Conditions
lymphangioleiomyomatosis (LAM)
Beyond the preview
Go deeper on NCT03062943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03062943.